Elix and University of Vienna Aim to Advance Drug Discovery Using AI
Elix and the University of Vienna will partner to bridge the gap between advanced structural biology and artificial intelligence. By integrating AI’s predictive power with experimental atomic-resolution data, the project seeks to bypass the limitations of traditional drug discovery, delivering new therapeutic insights for complex diseases. The post Elix and University of Vienna Aim to Advance…
Tokyo-based biotech company Elix and the University of Vienna have teamed up in a joint research agreement to push the boundaries of drug discovery using artificial intelligence. Elix’s flagship product, Elix Discovery, is an AI-powered platform designed to streamline the process of identifying optimal compounds for drug development.
The platform boasts an intuitive graphical user interface (GUI) that automates the creation of predictive models, allowing researchers to rapidly refine molecular designs with ease. Elix’s technology also excels in structure generation, generating novel compounds that may not have been conceived by human chemists alone.
The University of Vienna’s research arm, led by associate professor Julien Orts, brings a unique set of skills to the partnership. Orts’s lab specializes in nuclear magnetic resonance (NMR) spectroscopy techniques for decoding the atomic-resolution structures, dynamics, and interactions of biomacromolecules. In particular, Orts’s team has developed groundbreaking methods such as INPHARMA for validating small-molecule binding modes and NMR for determining protein-ligand structures accurately.
These methods have focused on studying protein conformational switches and allostery in signaling pathways, with applications in tackling undruggable targets.
This collaboration merges Elix’s AI-driven molecular generation capabilities with the University of Vienna’s expertise in structural dynamics and NMR-validated molecular interactions. By integrating the strengths of both parties, the joint research project aims to design and develop novel compounds targeting traditionally difficult targets, such as intrinsically disordered proteins (IDPs) and proteins involved in epigenetic signaling and cancer.
The combined forces of AI predictions and experimental atomic-resolution data will enable researchers to bypass the limitations of traditional drug discovery methods, potentially leading to breakthrough therapeutic insights and next-generation candidates for complex diseases. Both Elix CEO Shinya Yuki and Orts Lab leader Julien Orts expressed enthusiasm about the partnership, highlighting how it will accelerate the discovery of transformative medicines for the future.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
